PD-1/PD-L1-IN-NP19

• CAT Number: I033500
• CAS Number: 2377916-66-8
• Molecular Formula: C33H31ClN2O4
• Molecular Weight: 555.06
• Purity: ≥95%
• Synonyms: 2-[[5-chloro-2-[(3-cyanophenyl)methoxy]-4-[(2-methyl-3-phenylphenyl)methoxy]phenyl]methylamino]-2-methylpropanoic acid
• InChI: InChI=1S/C33H31ClN2O4/c1-22-26(13-8-14-28(22)25-11-5-4-6-12-25)21-40-31-17-30(39-20-24-10-7-9-23(15-24)18-35)27(16-29(31)34)19-36-33(2,3)32(37)38/h4-17,36H,19-21H2,1-3H3,(H,37,38)
• InChIKey: YZPKZNFXWGTUGO-UHFFFAOYSA-N
• SMILES: CC1=C(C=CC=C1C2=CC=CC=C2)COC3=C(C=C(C(=C3)OCC4=CC(=CC=C4)C#N)CNC(C)(C)C(=O)O)Cl

PD-1/PD-L1-IN-NP1（Cat No.:I033500）is a small-molecule inhibitor designed to block the interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, a key immune checkpoint pathway exploited by tumors to evade immune surveillance. By disrupting PD-1/PD-L1 binding, NP19 enhances T cell activation and restores antitumor immune responses. Researchers employ this compound to investigate checkpoint blockade mechanisms and to explore alternatives to monoclonal antibody therapies. Its selective activity makes it a valuable tool for immuno-oncology studies, advancing therapeutic strategies aimed at boosting immune-mediated tumor eradication.